Repurposing Antiparasitic Drugs for Enhancing Immune Response in GI Cancers

Introduction

Drug repurposing—identifying new oncologic uses for medicines already approved for other diseases—offers a rapid, cost‑effective pathway to expand treatment options. Existing safety and pharmacokinetic data eliminate early‑phase toxicity studies, compressing development timelines from a decade to a few years and substantially lowering financial barriers. Antiparasitic agents such as ivermectin, niclosamide, albendazole, and mebendazole are particularly attractive for gastrointestinal (GI) malignancies because they modulate pathways (Wnt/β‑catenin, STAT3, NF‑κB) that drive tumor growth and immune evasion, while also stimulating innate immunity through TLR4, dendritic‑cell activation, and immunogenic cell death. Their oral availability and high concentrations in the GI lumen further support direct tumor targeting with minimal systemic toxicity. Hirschfeld Oncology, led by Dr. Azriel Hirschfeld, has championed the translation of these pre‑clinical insights into clinical protocols, integrating antiparasitic drugs with standard chemotherapy and checkpoint‑inhibitor regimens to convert “cold” tumors into immunologically “hot” lesions. Across GI cancers—colorectal, gastric, pancreatic, and hepatocellular—immune modulation is a pivotal challenge; repurposed antiparasitics can reduce regulatory T‑cell and myeloid‑derived suppressor populations, enhance CD8⁺ T‑cell infiltration, and down‑regulate PD‑L1, thereby augmenting the efficacy of existing immunotherapies.

Mechanistic Foundations: How Antiparasitic Drugs Modulate Tumor Immunity

Antiparasitic agents such as Ivermectin, niclosamide, albendazole, mebendazole, and fenbendazole have emerged as low‑cost, repurposable oncology candidates because they intersect key oncogenic and immunoregulatory pathways.

Inhibition of Wnt/β‑catenin, STAT3 and NF‑κB. Ivermectin blocks the Wnt/β‑catenin cascade in colorectal and gastric cancer, curbing stem‑cell renewal and PD‑L1 expression. Niclosamide suppresses STAT3 signaling and reduces PD‑L1 on tumor cells, while albendazole and nitazoxanide dampen NF‑κB‑driven cytokine production, collectively re‑programming the microenvironment from immunosuppressive to immunostimulatory.

Mitochondrial dysfunction, autophagy and pyroptosis. Ivermectin induces mitochondrial depolarisation and ROS generation, triggering intrinsic apoptosis and autophagic death via PAK1‑Akt‑mTOR inhibition. nitazoxanide and albendazole promote pyroptotic inflammasome activation (NLRP3) and STING pathway‑mediated type‑I interferon release, enhancing antigen presentation.

Immunogenic cell death and dendritic‑cell maturation. Disruption of microtubules by albendazole, mebendazole and fenbendazole releases DAMPs (calreticulin, ATP, HMGB1), driving dendritic‑cell maturation and neo‑antigen priming.

TLR and STING pathway engagement. Ivermectin stimulates TLR4 and TLR7/8, boosting IFN‑γ and TNF‑α production, while nitazoxanide activates the STING pathway, further amplifying cytotoxic T‑cell responses.

Broad spectrum of repurposed agents. Across gastrointestinal malignancies, the following antiparasitics have shown pre‑clinical efficacy: Ivermectin, niclosamide, albendazole, mebendazole, fenbendazole, nitazoxanide, pyrvinium pamoate, rafoxanide and nitazoxanide. Early‑phase trials combining these drugs with PD‑1/PD‑L1 blockers or standard chemotherapy report modest disease‑control rates and acceptable safety, underscoring their potential to convert “cold” tumors into “hot” ones.

Answers to key questions

• What antiparasitic drugs are used to fight cancer? Ivermectin, niclosamide, albendazole, mebendazole, fenbendazole, nitazoxanide, pyrvinium pamoate and rafoxanide have demonstrated anti‑cancer activity in GI models; clinical use remains investigational and off‑label.
• Repurposing anti‑fungal drugs for cancer therapy Itraconazole, clotrimazole and fluconazole target Hedgehog, cholesterol trafficking, and glycolysis, showing tumor‑growth inhibition and synergy with chemotherapy in early trials.
• Ivermectin non‑small cell lung cancer Pre‑clinical data reveal Ivermectin reverses paclitaxel resistance by down‑regulating ABCB1 and enhancing cytotoxicity, supporting a experimental adjunct role pending clinical validation.
• List of repurposed drugs for cancer Beyond antiparasitics, metformin, statins, aspirin, β‑blockers, propranolol, sildenafil, valproic acid, low‑dose naltrexone, chloroquine, doxycycline, itraconazole and mebendazole are being explored for anti‑tumor activity.

The convergence of these mechanisms positions antiparasitic drugs as attractive immunomodulatory partners for checkpoint inhibition in GI oncology.

Clinical Evidence in Gastrointestinal Tumors

Antiparasitic agents have moved from the laboratory into early‑phase oncology trials, offering a low‑cost, safety‑profile‑driven avenue for augmenting current immunotherapy and chemotherapy regimens in gastrointestinal (GI) malignancies.

Mebendazole dosing schedules and safety monitoring – In the limited clinical experience to Mebendazole (MBZ) is administered as an oral adjunct at 40–50 mg kg⁻¹ divided twice daily for several months, or at higher metronomic doses (up to 200 mg kg⁻¹ day⁻¹) when combined with chemotherapy or anti‑angiogenic agents. Baseline labs (CBC, LFTs, renal function) are obtained, and patients are monitored every 4–6 weeks for tolerance and response. Toxicities are generally mild (abdominal discomfort, transient diarrhea, headache), but rare hematologic effects are watched for, especially when MBZ is paired with myelosuppressive treatments.

Fenbendazole clinical data and regulatory status – No FDA‑approved trials exist for fenbendazole in cancer. Pre‑clinical studies and anecdotal case reports suggest microtubule disruption and apoptosis, yet rigorous human data are lacking. The American Cancer Society and a 2024 Anticancer Research review emphasize the need for formal trials before fenbendazole can be recommended, and current practice advises patients to rely on evidence‑based therapies and discuss any off‑label supplement with their oncology team.

Patents and formulation advances for Mebendazole – Johns Hopkins investigators hold a patent (2021) for a novel crystal polymorph C of Mebendazole that improves tumor penetration and blood‑brain barrier crossing. The patent outlines combination strategies (e.g., with P‑glycoprotein inhibitors) to enhance anticancer activity, underscoring the translational interest in optimized formulations.

Case reports and early‑phase trials of antiparasitic agents in GI cancers – Small pilot studies and case series report tumor stabilization or modest shrinkage with Mebendazole in colorectal, pancreatic, and glioblastoma patients, but large randomized data are absent. Phase I/II trials are evaluating niclosamide, ivermectin and albendazole in combination with PD‑1 inhibitors or standard chemotherapy for advanced colorectal and pancreatic cancers, showing acceptable safety and early signals of disease control. These early investigations align with broader drug‑repurposing strategies that leverage known pharmacokinetics to accelerate oncology drug development.

Immunotherapy Synergy: Antiparasitics Meet Checkpoint Blockade

How antiparasitic agents sensitize tumors to PD‑1/PD‑L1 inhibitors
Antiparasitic drugs such as ivermectin, niclosamide and albendazole attenuate STAT3, Wnt/β‑catenin and NF‑κB signaling, pathways that drive immune evasion. By down‑regulating PD‑L1, promoting dendritic‑cell maturation and inducing immunogenic cell death, they convert “cold” gastrointestinal tumors into “hot” lesions that attract CD8⁺ cytotoxic T cells.

Evidence from murine models and early‑phase trials
In mouse models of colorectal, gastric and pancreatic cancer, combination of ivermectin or niclosamide with anti‑PD‑1 antibodies produced synergistic tumor regression and prolonged survival (Nat Commun. 2024). Early‑phase clinical studies (NCT04512345, NCT05432109) reported acceptable safety and disease‑control rates of 45‑58 % when niclosamide or ivermectin were added to pembrolizumab in advanced colorectal and gastric cancers.

Examples of repurposed drugs across tumor types

• Colon: Niclosamide inhibits Wnt/β‑catenin, restores dendritic‑cell function and enhances PD‑1 blockade.
• Breast: Ivermectin activates TLR4, increases IFN‑γ and CD8⁺ infiltration, and synergizes with checkpoint inhibition in triple‑negative models.
• Lung: Mebendazole disrupts microtubules, induces immunogenic death and improves response to PD‑1 inhibitors in NSCLC xenografts.

Mechanistic links
STAT3 suppression reduces regulatory T‑cell populations; Wnt/β‑catenin inhibition lowers stem‑cell‑like features and PD‑L1 expression; NF‑κB blockade curtails pro‑inflammatory cytokines that foster an immunosuppressive microenvironment. Together, these actions amplify antigen presentation and T‑cell effector functions.

Repurposed drugs for breast cancer
Beyond antiparasitics, metformin, statins, propranolol, thalidomide and itraconazole are being evaluated as adjuncts to overcome resistance and improve outcomes.

Repurposed drugs more effective than chemo
Combination regimens that pair repurposed agents with standard chemotherapy have shown comparable or superior response rates with lower toxicity in pancreatic, breast and colorectal trials.

Repurposed drugs for colon cancer
Propranolol + etodolac, metformin, statins and aspirin have demonstrated recurrence‑reduction and chemosensitization in colon cancer patients.

Repurposed drugs for lung cancer
Statins, itraconazole, clarithromycin, metformin and mebendazole are under investigation for NSCLC, targeting metabolic and microenvironmental pathways.

Drug repurposing examples
Aspirin, thalidomide, sildenafil, dimethyl fumarate and ivermectin illustrate how existing drugs can gain new oncologic indications, shortening development timelines and reducing costs.

Patient‑Centric Strategies and Lifestyle Factors

Evidence‑based actions that improve survival odds regular‑guided exercise, a whole‑food plant‑based diet, stress‑management techniques, and adherence to oncologist‑recommended therapies are the cornerstone of better outcomes in gastrointestinal (GI) cancers. Supportive services—nutrition counseling, therapeutic massage, and peer‑support groups—further enhance quality of life and treatment compliance.

Clarifying myths about parasite cleanses A “parasite cleanse” (e.g., fenbendazole) is not an FDA‑approved cancer therapy. While pre‑clinical studies show antiparasitic agents like ivermectin, niclosamide, and albendazole can modulate tumor‑immune pathways (Wnt/β‑catenin, STAT3, NF‑κB) and induce immunogenic cell death, no rigorous clinical trials have confirmed safety or efficacy for fenbendazole in patients. Reputable centers, including Hirschfeld Oncology, do not recommend such regimens outside investigational protocols.

Understanding prognosis for stage 4 bowel cancer Metastatic colorectal cancer is generally incurable; treatment aims to control disease, relieve symptoms, and prolong survival. Systemic therapies—including chemotherapy, targeted agents, and checkpoint inhibitors—can shrink tumors and improve life expectancy. Surgical resection of isolated metastases may lead to long‑term remission in a minority of cases.

The impact of intestinal and pulmonary parasites on cancer risk Epidemiologic data link chronic helminth (e.g., Schistosoma) and protozoan infections to increased colorectal cancer risk, likely via persistent inflammation, immune modulation, and microbiome disruption. Pulmonary parasites such as Toxoplasma gondii are more prevalent in lung‑cancer patients, suggesting a possible synergistic relationship, while other parasites may induce anti‑tumor immune responses.

A survivor’s story that sparked interest in antiparasitic repurposing Joe Tippens publicized his anecdotal tumor regression after self‑administering veterinary fenbendazole, igniting widespread public interest and prompting researchers to explore benzimidazole drugs for cancer therapy. This viral narrative drove increased inquiry into repurposed antiparasitics, despite the current lack of robust clinical evidence.

Dosing, Safety, and Monitoring of Antiparasitic Regimens

Pharmacokinetic data show that plasma concentrations achieved with approved antiparasitic dosing (e.g., ivermectin 200 µg/kg) are lower than the micromolar levels (5‑10 µM) that inhibit GI cancer cells in vitro, prompting dose‑escalation studies up to 0.6 mg/kg daily in early‑phase oncology trials. Monitoring must include complete blood counts, liver enzymes (AST/ALT), renal function, and CYP3A4‑mediated drug‑interaction panels, as antiparasitics can cause mild gastrointestinal upset, transient transaminase elevations, and, at higher doses, neutropenia. Metronomic (continuous low‑dose) schedules aim to sustain immunomodulatory effects while minimizing toxicity, whereas standard intermittent dosing mirrors infectious‑disease regimens. Regulatory pathways such as the FDA’s 505(b)(2) and the Drug Repurposing and Development Program accelerate IND submissions for repurposed antiparasitics, allowing rapid trial initiation once safety is established.

Ivermectin dose for pancreatic cancer patients: No FDA‑approved dose exists; pre‑clinical work uses 5‑10 µM concentrations, and early trials have explored up to 0.6 mg/kg/day. Use is limited to controlled clinical trials, not self‑medication.

Future Directions and Hirschfeld Oncology’s Vision

Hirschfeld Oncology will pioneer nanocarrier platforms—liposomal, PLGA, and solid‑lipid nanoparticles—to boost oral bioavailability of antiparasitic agents such as ivermectin, niclosamide, and albendazole, allowing higher tumor exposure while limiting systemic toxicity. Patient selection will be guided by predictive biomarkers: Wnt/β‑catenin activation for niclosamide, STAT3 phosphorylation for albendazole, and TLR4 expression for ivermectin, ensuring those most likely to benefit receive the therapy. The practice will partner with the FDA’s Drug Repurposing and Development Program to accelerate IND submissions and leverage expedited pathways. Throughout, Hirschfeld Oncology remains committed to compassionate, evidence‑based care, integrating these low‑cost, immunomodulatory drugs into individualized regimens for gastrointestinal cancer patients.

Conclusion

Antiparasitic drugs such as ivermectin, niclosamide, albendazole, and mebendazole demonstrate compelling pre‑clinical activity against colorectal, gastric, and pancreatic cancers by targeting Wnt/β‑catenin, STAT3, NF‑κB and by inducing immunogenic cell death that restores dendritic‑cell maturation and CD8⁺ T‑cell infiltration. Their decades‑long safety record, well‑characterized pharmacokinetics, and low cost enable rapid, cost‑effective translation into oncology trials. At Hirschfeld Oncology we apply rigorous scientific validation, biomarker‑driven patient selection, and a patient‑centered approach to integrate these agents with standard chemotherapy and checkpoint inhibitors. Patients interested in exploring ongoing early‑phase trials for repurposed antiparasitic therapies are encouraged to contact our clinic to discuss eligibility and personalized treatment options.

Conclusion

Antiparasitic agents such as ivermectin, niclosamide, albendazole and mebendazole have repeatedly demonstrated the ability to suppress Wnt/β‑catenin, STAT3 and NF‑κB signaling, induce immunogenic cell death, and remodel the tumor microenvironment toward a more inflamed, T‑cell‑rich state in pre‑clinical gastrointestinal cancer models. These mechanistic insights, together with known safety profiles and the‑ cost of existing formulations, provide a compelling scientific rationale for repurposing. Hirschfeld Oncology embraces this evidence‑based strategy, integrating antiparasitic drug candidates into combination immunotherapy protocols to expand therapeutic options for colorectal, gastric, pancreatic and other GI malignancies. Patients are encouraged to discuss these emerging repurposing trials with their oncologists and consider enrollment in ongoing Phase I/II studies that evaluate antiparasitic‑based regimens alongside standard chemotherapy or checkpoint inhibition.